Markovic S N, Erickson L A, Flotte T J, Kottschade L A, McWilliams R R, Jakub J W, Farley D R, Tran N V, Schild S E, Olivier K R, Vuk-Pavlovic S, Sekulic A, Weenig R H, Pulido J S, Quevedo J F, Vile R G, Wiseman G A, Stoian I, Pittelkow M R
Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.
G Ital Dermatol Venereol. 2009 Feb;144(1):1-26.
Metastatic malignant melanoma is an incurable malignancy with extremely poor prognosis. Patients bearing this diagnosis face a median survival time of approximately 9 months with a probability of surviving 5 years after initial presentation at less than 5%. This is contrasted by the curative nature of surgical resection of early melanoma detected in the skin. To date, no systemic therapy has consistently and predictably impacted the overall survival of patients with metastatic melanoma. However, in recent years, a resurgence of innovative diagnostic and therapeutic developments have broadened our understanding of the natural history of melanoma and identified rational therapeutic targets/strategies that seem poised to significantly change the clinical outcomes in these patients. Herein we review the state-of-the-art in metastatic melanoma diagnostics and therapeutics with particular emphasis on multi-disciplinary clinical management.
转移性恶性黑色素瘤是一种无法治愈的恶性肿瘤，预后极差。被诊断为此病的患者中位生存时间约为9个月，初次就诊后存活5年的概率不到5%。相比之下，皮肤中早期黑色素瘤的手术切除具有治愈性。迄今为止，尚无系统性疗法能持续且可预测地影响转移性黑色素瘤患者的总生存期。然而，近年来，创新性诊断和治疗进展的复兴拓宽了我们对黑色素瘤自然病史的理解，并确定了合理的治疗靶点/策略，这些似乎有望显著改变这些患者的临床结局。在此，我们综述转移性黑色素瘤诊断和治疗的最新进展，尤其强调多学科临床管理。
